NEWS | alsv | Page 13 of 18

Companies in the News

Sep 28, 2018

Gritstone Oncology Announces Pricing of Initial Public Offering

EMERYVILLE, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq:GRTS) today announced the pricing of its initial...

Sep 20, 2018

Indigo Agriculture Launches Indigo Certified Crops™, an Offer to Increase Grower Profitability and M

Indigo Certified Crops™ is a new offer for U.S. growers, integrating the company’s microbial and digital technologies with the newly...

Sep 18, 2018

Indigo Agriculture Raises an Additional $250M and Launches Digital Grain Marketplace

Indigo extends efforts to decommoditize agriculture with launch of Indigo Marketplace™, a digital platform for buying and selling grain...

Sep 13, 2018

Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with

ANN ARBOR, Mich., September 13, 2018 – Millendo Therapeutics, Inc., a clinicalstage biopharmaceutical company focused on developing novel...

Sep 13, 2018

2018 Indigo Wheat™ Harvest Data Demonstrates Significant Yield and Quality Improvements Across more

Leveraging satellite technology, Indigo releases data on an unprecedented 40,000+ acres from the 2018 commercial wheat harvest Indigo...

Aug 23, 2018

bluebird bio and Gritstone Oncology Announce Strategic Collaboration to Develop Novel Cancer Cell Th

CAMBRIDGE, Mass. & EMERYVILLE, Calif.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) and Gritstone Oncology, Inc. today announced a...

Aug 10, 2018

OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Compan

Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi...

Jul 30, 2018

Omniome Completes $60 Million Series B Financing To Advance Novel Genomic Sequencing Technology

SAN DIEGO, July 30, 2018 /PRNewswire/ -- Omniome, Inc., developer of an innovative new DNA sequencing platform, today announced it has...

Jul 27, 2018

eFFECTOR Initiates Dosing of eFT508 (tomivosertib) in a Phase 2 Add-on (CPI-A) Trial in Combination

SAN DIEGO, July 27, 2018 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the...